Neuphoria Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Sep 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Sep 29, 2025
NEUP$2.76-0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| June 30, | June 30, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $14,210,745 | $12,608,109 |
| Accounts receivable, non-trade | 11,948 | 126,884 |
| Restricted cash | 77,945 | — |
| Prepaid expenses | 740,193 | 458,765 |
| Total current assets | 15,040,831 | 13,193,758 |
| Property and equipment, net | 2,771 | 1,994 |
| Intangible assets, net | 4,804,791 | 5,467,522 |
| Operating lease right-of-use assets | 102,612 | 216,975 |
| Restricted cash | — | 78,826 |
| Goodwill | 8,638,609 | 8,690,018 |
| Total assets | $28,589,614 | $27,649,093 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,154,369 | $2,243,662 |
| Accrued expenses and other current liabilities | 2,950,077 | 1,463,421 |
| Operating lease liability | 116,314 | 121,990 |
| Total current liabilities | 4,220,760 | 3,829,073 |
| Operating lease liability, net of current portion | — | 117,628 |
| Contingent consideration | 1,169,675 | 587,762 |
| Deferred tax liability | 495,113 | 963,540 |
| Accompanying warrant liability | 3,701,492 | 4,657,832 |
| Other non-current liabilities | — | 2,886 |
| Total liabilities | 9,587,040 | 10,158,721 |
| Commitments and contingencies (Note 17) | ||
| Shareholders’ equity: | ||
| Common stock, $0.00001 par value, 1,978,460 and 1,103,954 shares issued and outstanding at June 30, 2025 and 2024, respectively | 19 | 11 |
| Additional paid-in capital, net of subscription receivable | 200,194,324 | 198,481,027 |
| Accumulated other comprehensive loss, net of tax | (2,845,066) | (3,013,595) |
| Accumulated deficit | (178,346,703) | (177,977,071) |
| Total shareholders’ equity | 19,002,574 | 17,490,372 |
| Total liabilities and shareholders’ equity | $28,589,614 | $27,649,093 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.